GSK plc reports

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

30 Oct 2024

Reporting date

30 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

3RD QUARTER RESULTS

Filing date

30 Oct 2024

Reporting date

30 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK

Filing date

24 Oct 2024

Reporting date

24 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

17 Oct 2024

Reporting date

17 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

16 Oct 2024

Reporting date

16 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN

Filing date

16 Oct 2024

Reporting date

16 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

15 Oct 2024

Reporting date

15 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB

Filing date

15 Oct 2024

Reporting date

15 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

11 Oct 2024

Reporting date

11 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

10 Oct 2024

Reporting date

10 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS

Filing date

09 Oct 2024

Reporting date

09 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS

Filing date

08 Oct 2024

Reporting date

08 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

4 File 001-37627

WVE - CHANGE IN BENEFICIAL OWNERSHIP

Filing date

01 Oct 2024

Reporting date

27 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date

01 Oct 2024

Reporting date

01 Oct 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

24 Sep 2024

Reporting date

24 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE

Filing date

24 Sep 2024

Reporting date

24 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

STATEMENT: ZANTAC (RANITIDINE) LITIGATION

Filing date

18 Sep 2024

Reporting date

18 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA

Filing date

17 Sep 2024

Reporting date

17 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP

Filing date

13 Sep 2024

Reporting date

13 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

12 Sep 2024

Reporting date

12 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA

Filing date

12 Sep 2024

Reporting date

12 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

STATEMENT: ZANTAC (RANITIDINE) LITIGATION

Filing date

11 Sep 2024

Reporting date

11 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

CHANGE OF REGISTERED OFFICE

Filing date

11 Sep 2024

Reporting date

11 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL

Filing date

11 Sep 2024

Reporting date

11 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS

Filing date

09 Sep 2024

Reporting date

09 Sep 2024

SEC evidence

Open document Open filing

Next action

Verify source filing